Analysts forecast that Uniqure NV (NASDAQ:QURE) will report sales of $3.55 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Uniqure’s earnings, with estimates ranging from $3.50 million to $3.60 million. Uniqure posted sales of $4.94 million during the same quarter last year, which would indicate a negative year over year growth rate of 28.1%. The firm is scheduled to report its next earnings report on Tuesday, August 14th.
On average, analysts expect that Uniqure will report full year sales of $17.44 million for the current fiscal year, with estimates ranging from $13.98 million to $26.00 million. For the next fiscal year, analysts expect that the firm will report sales of $13.23 million per share, with estimates ranging from $10.00 million to $16.90 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Uniqure.
Uniqure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, April 30th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.15. The firm had revenue of $3.48 million during the quarter, compared to the consensus estimate of $3.08 million. Uniqure had a negative return on equity of 131.55% and a negative net margin of 586.38%.
A number of brokerages recently issued reports on QURE. ValuEngine raised Uniqure from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. HC Wainwright set a $35.00 price objective on Uniqure and gave the company a “buy” rating in a report on Tuesday, May 1st. Leerink Swann reissued an “outperform” rating and issued a $63.00 price objective (up from $26.00) on shares of Uniqure in a report on Monday, May 7th. BidaskClub downgraded Uniqure from a “buy” rating to a “hold” rating in a report on Saturday, March 17th. Finally, Wells Fargo assumed coverage on Uniqure in a report on Wednesday, May 16th. They issued an “outperform” rating and a $47.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $30.88.
In other news, CEO Matthew C. Kapusta sold 39,169 shares of the stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $21.72, for a total value of $850,750.68. Following the completion of the sale, the chief executive officer now directly owns 439,764 shares of the company’s stock, valued at $9,551,674.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.73% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Opaleye Management Inc. acquired a new stake in shares of Uniqure during the fourth quarter worth $1,778,000. Royce & Associates LP acquired a new stake in shares of Uniqure during the fourth quarter worth $2,449,000. Victory Capital Management Inc. acquired a new stake in shares of Uniqure during the fourth quarter worth $1,298,000. Perceptive Advisors LLC lifted its holdings in shares of Uniqure by 0.8% during the fourth quarter. Perceptive Advisors LLC now owns 1,047,950 shares of the biotechnology company’s stock worth $20,529,000 after purchasing an additional 7,831 shares during the period. Finally, Tekla Capital Management LLC lifted its holdings in shares of Uniqure by 38.1% during the fourth quarter. Tekla Capital Management LLC now owns 332,850 shares of the biotechnology company’s stock worth $6,521,000 after purchasing an additional 91,829 shares during the period. 43.83% of the stock is owned by hedge funds and other institutional investors.
Uniqure traded up $0.07, reaching $31.38, on Friday, according to Marketbeat. The company’s stock had a trading volume of 14,294 shares, compared to its average volume of 390,560. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -10.71 and a beta of 0.15. Uniqure has a fifty-two week low of $4.90 and a fifty-two week high of $33.41.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.